BioCentury
ARTICLE | Clinical News

Applied Genetic slides after clinical updates

September 13, 2016 7:00 AM UTC

Applied Genetic Technologies Corp. (NASDAQ:AGTC) fell $4.19 (32%) to $9 on Tuesday after it said enrollment was slower than expected in two Phase I/II studies of its ocular gene therapy candidates. One of the studies has yet to show improvements on secondary endpoints tied to potential efficacy, the company said. AGTC announced the news after market close Monday along with FY16 financial results for the year ended June 30.

The company has enrolled eight of a maximum 27 patients in its study of XLRS ( rAAV2tYF-CB-hRS1) to treat X-linked retinoschisis (XLRS), including six in a low-dose cohort. The company intends to add trial sites and enhance its outreach programs, and has made a protocol amendment allowing use of prophylactic corticosteroids. AGTC also said it had to "re-test the study agent for a process component" due to vendor errors. ...